Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.46 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 7/20 | 0.41 |
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.37 |
| ▸ | PNMT | P11086 | 1/20 | 0.35 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.35 |
| ▸ | HTR3B | O95264 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.35 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15812201 | 0.90 | TNKS (0.49) | TNKSTNKS2HTR2CHTR2APKM | |
| SCHEMBL13387691 | 0.87 | HTR2C (0.44) | TNKSTNKS2HTR2CHTR2AHTR2B | |
| SCHEMBL15811993 | 0.86 | TNKS (0.50) | TNKSTNKS2AVPR1APDE7ACMA1 | |
| SCHEMBL15812245 | 0.86 | TNKS (0.50) | TNKSTNKS2HTR2CHTR2AHTR2B | |
| SCHEMBL26418980 | 0.80 | PNMT (0.39) | TNKSTNKS2HTR2CHTR2AHTR2B | |
| SCHEMBL11090651 | 0.80 | TNKS (0.51) | TNKSTNKS2AVPR1ACMA1AHR | |
| SCHEMBL1195633 | 0.76 | TNKS (0.40) | TNKSTNKS2PKMAVPR1A | |
| SCHEMBL1195631 | 0.76 | TNKS (0.40) | TNKSTNKS2PKMAVPR1A | |
| SCHEMBL13330233 | 0.76 | — | — | |
| SCHEMBL17160763 | 0.75 | CMA1 (0.40) | TNKSTNKS2HTR2CHTR2AAVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370423-A1 | METHOD FOR PREPARING A SPIROINDOLINE AND A PRECURSOR THEREOF | Glaxo Group Limited (GB) | 2011-10-05 | — | — | EP | claimed |
| US-20110230660-A1 | METHOD FOR PREPARING A SPIROINDOLINE AND A PRECURSOR THEREOF | Method for Preparing a Spiroindoline | 2011-09-22 | — | — | US | claimed |
| WO-2010065704-A1 | METHOD FOR PREPARING A SPIROINDOLINE AND A PRECURSOR THEREOF | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | WO | claimed |
| US-8563722-B2 | Stereoselective hydrogenation of a ketone | GLAXO GROUP LIMITED (GB) | 2013-10-22 | — | — | US | disclosed |
| US-8563722-B2 | Stereoselective hydrogenation of a ketone | GLAXO GROUP LIMITED (GB) | 2013-10-22 | — | — | US | disclosed |
| US-8431590-B2 | Spiroindolines as modulators of chemokine receptors | GLAXO GROUP LIMITED (GB) | 2013-04-30 | — | — | US | disclosed |
| US-8431590-B2 | Spiroindolines as modulators of chemokine receptors | GLAXO GROUP LIMITED (GB) | 2013-04-30 | — | — | US | disclosed |
| US-8431590-B2 | Spiroindolines as modulators of chemokine receptors | GLAXO GROUP LIMITED (GB) | 2013-04-30 | — | — | US | disclosed |
| EP-2400844-A1 | STEREOSELECTIVE HYDROGENATION OF A KETONE | Glaxo Group Limited (GB) | 2012-01-04 | — | — | EP | disclosed |
| US-20110306765-A1 | STEREOSELECTIVE HYDROGENATION OF A KETONE | GLAXO GROUP LIMITED (GB) | 2011-12-15 | — | — | US | disclosed |
| US-20110306765-A1 | STEREOSELECTIVE HYDROGENATION OF A KETONE | GLAXO GROUP LIMITED (GB) | 2011-12-15 | — | — | US | disclosed |
| US-7723350-B2 | Spiroindolines as modulators of chemokine receptors | GLAXO GROUP LIMITED (GB) | 2010-05-25 | — | — | US | disclosed |
| US-7723350-B2 | Spiroindolines as modulators of chemokine receptors | GLAXO GROUP LIMITED (GB) | 2010-05-25 | — | — | US | disclosed |
| US-7723350-B2 | Spiroindolines as modulators of chemokine receptors | GLAXO GROUP LIMITED (GB) | 2010-05-25 | — | — | US | disclosed |
| EP-2166848-A1 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | Glaxo Group Limited (GB) | 2010-03-31 | — | — | EP | disclosed |
| US-20080318990-A1 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
| US-20080318990-A1 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
| US-20080318990-A1 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2008-12-25 | — | — | US | disclosed |
| WO-2008157741-A1 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008157741-A1 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318990-A1 | SPIROINDOLINES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CCR10, CXCR2 | TNKS 4454/4885TNKS2 4488/4885HTR2C 961/4885 |
| US-20110230660-A1 | METHOD FOR PREPARING A SPIROINDOLINE AND A PRECURSOR THEREOF | CCR2, CXCR4, CXCR2 | TNKS 3082/4885TNKS2 3678/4885HTR2C 339/4885 |
| US-20110306765-A1 | STEREOSELECTIVE HYDROGENATION OF A KETONE | CCR2, CX3CR1, CCR1 | TNKS 4276/4885TNKS2 4210/4885HTR2C 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.